- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04630015 | Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth | completed | — | 134 | University of California, San FranciscoOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH |
| 1 |
| Apr 26, 2023 |
| clinicaltrials |
| NCT02754141 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab | completed | Phase 1 / Phase 2 | 235 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 5, 2023 | clinicaltrials |
| NCT03756818 | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04938869 | Continuous Glucose Monitor Application After Hospital Discharge for the Improvement of Outcomes in Patients With Poorly Controlled Type 2 Diabetes and Active Cancer | completed | N/A | 3 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT01023737 | Hydroxychloroquine + Vorinostat in Advanced Solid Tumors | completed | Phase 1 | 72 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT02959905 | Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes) | completed | Phase 1 | 11 | BGI, ChinaOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT01822522 | Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT03237390 | Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT00909740 | A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Genentech, Inc.INDUSTRY | 0 | Dec 12, 2022 | clinicaltrials |
| NCT03980535 | New Magnetic Resonance Imaging and Spectroscopy Software in the Improvement of Image Quality | completed | N/A | 273 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02252211 | Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers(LUD2014-002) | completed | Phase 1 | 9 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04759183 | Virtual Reality Experiences for Anxiety and Pain Control | completed | N/A | 32 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT04208724 | Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization | completed | N/A | 35 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT02227940 | Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 38 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03430882 | Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors | completed | Phase 1 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02451553 | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer | completed | Phase 1 | 41 | University of WashingtonOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT02686411 | Evaluation of Satisfaction With Quality of Care on the Palliative Care Unit | completed | — | 35 | M.D. Anderson Cancer CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03551795 | Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor | completed | Phase 1 / Phase 2 | 8 | Xiaoyan ZhangOTHER_GOV | 1 | May 9, 2022 | clinicaltrials |
| NCT02923466 | Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors | completed | Phase 1 | 76 | Vyriad, Inc.INDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT04870320 | Study of Attention and Memory Treatments for Cancer Survivors | completed | N/A | 49 | University of California, San FranciscoOTHER | 1 | Apr 8, 2022 | clinicaltrials |
| NCT05060328 | Use of Google Translate to Enhance Patient Pain and Nausea Assessment and Satisfaction After General Anesthesia | completed | — | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT01515306 | A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors | completed | Phase 2 | 48 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT01337505 | Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 24 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT04652505 | Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study | completed | — | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT04328506 | Bioequivalency Study of CM082 Tablet in Healthy Volunteers | completed | Phase 1 | 96 | AnewPharmaINDUSTRY | 1 | Nov 26, 2021 | clinicaltrials |
| NCT03905720 | Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services(PRACXIS) | completed | N/A | 448 | University of California, San FranciscoOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT01457118 | An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies | completed | Phase 2 | 27 | Nektar TherapeuticsINDUSTRY | 2 | Jul 12, 2021 | clinicaltrials |
| NCT04439240 | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2021 | clinicaltrials |
| NCT00452413 | A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | completed | Phase 1 / Phase 2 | 65 | Eli Lilly and CompanyINDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT03009214 | A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours | completed | Phase 1 | 55 | amcure GmbHINDUSTRY | 2 | May 10, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT01765790 | Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors | completed | Phase 1 | 68 | Baxalta now part of ShireINDUSTRY | 2 | May 5, 2021 | clinicaltrials |
| NCT04439214 | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
| NCT01554371 | Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 44 | University of California, San FranciscoOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT02152943 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02902237 | tTF-NGR Phase I Study | completed | Phase 1 | 24 | University Hospital MuensterOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03512340 | Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | completed | Phase 1 | 148 | Surface OncologyINDUSTRY | 2 | Oct 20, 2020 | clinicaltrials |
| NCT00836888 | ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan | completed | Phase 1 | 17 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03553108 | A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.(IVIVC) | completed | Phase 1 | 18 | AstraZenecaINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT02857920 | Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 45 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT02323191 | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | completed | Phase 1 | 221 | Hoffmann-La RocheINDUSTRY | 4 | Aug 27, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT02843204 | Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 110 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04126668 | A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers | completed | Phase 1 | 24 | AnewPharmaINDUSTRY | 1 | May 21, 2020 | clinicaltrials |
| NCT02174172 | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 158 | Hoffmann-La RocheINDUSTRY | 2 | May 12, 2020 | clinicaltrials |
| NCT01435096 | BN80927 in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 56 | IpsenINDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT02518958 | A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab(PRIMETIME) | completed | Phase 1 | 12 | EpicentRx, Inc.INDUSTRY | 1 | Nov 18, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 9, 2023source: clinicaltrials